Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals Stock Up 0.5 %
MACK Stock opened at $4.22 on Friday. Merrimack Pharmaceuticals has a 12-month low of $3.66 and a 12-month high of $7.41. The company has a market cap of $56.59 million, a price-to-earnings ratio of -35.17 and a beta of 1.32. The company has a 50 day moving average of $5.39 and a two-hundred day moving average of $5.72.
Analyst Ratings Changes
Separately, StockNews.com started coverage on shares of Merrimack Pharmaceuticals in a research report on Tuesday. They issued a "sell" rating for the company.
Insider Activity
In other Merrimack Pharmaceuticals news, Director Noah G. Levy purchased 20,938 shares of the business's stock in a transaction dated Tuesday, June 14th. The shares were acquired at an average price of $5.17 per share, for a total transaction of $108,249.46. Following the acquisition, the director now owns 1,010,515 shares of the company's stock, valued at $5,224,362.55. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have acquired 35,478 shares of company stock worth $188,276. 25.80% of the stock is owned by corporate insiders.